A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS)

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to determine the efficacy and safety of the drug romiplositim for treatment of thrombocytopenia (reduced platelet count) in patients with low or intermediate -1 risk myelodysplastic syndrome (MDS).

Disease Status and/or Stage

Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Key Eligibility

  • Men and women age 18 to 90
  • Diagnosed with myelodysplastic syndrome (MDS)
  • Low or intermediate-1 risk MDS as assessed during the screening period
  • More detailed eligibility discussed when you contact the study team

Principal Investigator

Gail Roboz, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page